Clarke A. Low, MD
Overall survival (OS) from the phase III FLAURA trial have confirmed osimertinib (Tagrisso) as the new standard frontline treatment for patients with EGFR
-mutated non–small cell lung cancer (NSCLC), said Clarke A. Low, MD, adding that the drug’s tolerability plus its central nervous system (CNS) activity sets it apart from other available TKIs.
... to read the full story